Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

ME Staff 8-k
-
0
Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item 8.01. Other Events.

On October11, 2018, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing that it will focus on its growing core central nervous system (“CNS”) portfolio, and that as a result, the Company has created Axsome Pain and Primary Care (“Axsome PPC”), a new business unit to house, manage, develop and enhance the value of the Company’s non-CNS assets. The assets in Axsome PPC include the Company’s pain and primary care product candidates and related intellectual property.

The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit Number

Description

99.1

Press release dated October11, 2018.


Axsome Therapeutics, Inc. Exhibit
EX-99.1 2 a18-36607_1ex99d1.htm EX-99.1 Exhibit 99.1     Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets   Axsome PPC to include three novel,…
To view the full exhibit click here

About Axsome Therapeutics,Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).